Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

BACKGROUND: Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechalle...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Immunother Cancer
Główni autorzy: Siddiqui, Bilal A, Gheeya, Jinesh S, Goswamy, Rohit, Bathala, Tharakeswara K, Surasi, Devaki Shilpa, Gao, Jianjun, Shah, Amishi, Campbell, Matthew T, Msaouel, Pavlos, Goswami, Sangeeta, Wang, Jennifer, Zurita, Amado J, Jonasch, Eric, Corn, Paul G, Aparicio, Ana M, Siefker-Radtke, Arlene O, Sharma, Padmanee, Subudhi, Sumit K, Tannir, Nizar
Format: Artigo
Język:Inglês
Wydane: BMJ Publishing Group 2021
Hasła przedmiotowe:
Clinical/Translational Cancer Immunotherapy
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://ncbi.nlm.nih.gov/pubmed/34326169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002850
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy